272 related articles for article (PubMed ID: 31439581)
21. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
22. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
23. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3.
Zhao K; Dai Q; Wu J; Wei Z; Duan Y; Chen B
Eur J Cancer; 2022 Apr; 165():58-70. PubMed ID: 35219024
[TBL] [Abstract][Full Text] [Related]
24. A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.
Galbán S; Apfelbaum AA; Espinoza C; Heist K; Haley H; Bedi K; Ljungman M; Galbán CJ; Luker GD; Dort MV; Ross BD
Mol Cancer Ther; 2017 Nov; 16(11):2340-2350. PubMed ID: 28775144
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
Corazao-Rozas P; Guerreschi P; André F; Gabert PE; Lancel S; Dekiouk S; Fontaine D; Tardivel M; Savina A; Quesnel B; Mortier L; Marchetti P; Kluza J
Oncotarget; 2016 Jun; 7(26):39473-39485. PubMed ID: 27250023
[TBL] [Abstract][Full Text] [Related]
26. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
27. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
29. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.
Girard CA; Lecacheur M; Ben Jouira R; Berestjuk I; Diazzi S; Prod'homme V; Mallavialle A; Larbret F; Gesson M; Schaub S; Pisano S; Audebert S; Mari B; Gaggioli C; Leucci E; Marine JC; Deckert M; Tartare-Deckert S
Cancer Res; 2020 May; 80(10):1927-1941. PubMed ID: 32179513
[TBL] [Abstract][Full Text] [Related]
30. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
31. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
32. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
33. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
34. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).
Germann UA; Furey BF; Markland W; Hoover RR; Aronov AM; Roix JJ; Hale M; Boucher DM; Sorrell DA; Martinez-Botella G; Fitzgibbon M; Shapiro P; Wick MJ; Samadani R; Meshaw K; Groover A; DeCrescenzo G; Namchuk M; Emery CM; Saha S; Welsch DJ
Mol Cancer Ther; 2017 Nov; 16(11):2351-2363. PubMed ID: 28939558
[TBL] [Abstract][Full Text] [Related]
35. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
[TBL] [Abstract][Full Text] [Related]
36. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
37. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Wang L; Leite de Oliveira R; Huijberts S; Bosdriesz E; Pencheva N; Brunen D; Bosma A; Song JY; Zevenhoven J; Los-de Vries GT; Horlings H; Nuijen B; Beijnen JH; Schellens JHM; Bernards R
Cell; 2018 May; 173(6):1413-1425.e14. PubMed ID: 29754815
[TBL] [Abstract][Full Text] [Related]
38. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
39. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.
Marchetti P; Trinh A; Khamari R; Kluza J
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):999-1005. PubMed ID: 29413908
[TBL] [Abstract][Full Text] [Related]
40. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.
Asundi J; Lacap JA; Clark S; Nannini M; Roth L; Polakis P
Mol Cancer Ther; 2014 Jun; 13(6):1599-610. PubMed ID: 24651527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]